Immunovant

Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of commercializing the drug

James Waldron Apr 2, 2026 7:27am

Immunovant narrows R&D focus as Roivant execs join C-suite

Apr 21, 2025 10:00am

Immunovant posts phase 3 autoimmune win but won't seek approval

Mar 19, 2025 9:15am

long distance runners race ultramarathon marathon

Immunovant promotes next-gen FcRn drug in race to rival Vyvgart

May 30, 2024 7:02am

light idea burst ruin destroy lightning shot

JPM24: Roivant CEO has ‘pangs of regret’ for letting Telavant go

Jan 12, 2024 10:30am

An arrow incrementally going up stairs before pointing straight up Blue background

Immunovant posts midphase FcRn data in Graves’, plots next steps

Dec 21, 2023 7:00am